Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics sets retention program for CEO and chief legal officer

Neutral Impact 3 of 5 leadership Written later

TScan Therapeutics' Compensation Committee approved a key employee retention program on September 8, 2026, covering CEO Gavin MacBeath and Chief Legal and Strategy Officer Zoran Zdraveski. The program provides cash awards and potential future equity grants, with part of the cash tied to a clinical milestone and the equity tied to a financing milestone.

Key points

  • Dr. MacBeath cash award of $822,000; Dr. Zdraveski cash award of $416,000
  • Dr. MacBeath to receive 2,400,000 RSUs; Dr. Zdraveski to receive 1,050,000 RSUs under the 2021 Plan
  • One-third of the first half of cash awards paid in November 2026, two-thirds in February 2027; second half tied to a clinical milestone
  • One-third of RSUs vest on a financing milestone; remaining two-thirds vest over first and second anniversaries of that milestone

The filing

CompanyTScan Therapeutics, Inc. (TCRX)
Form8-K, current report
Filed with the SECSep 11, 2026, 8:00 AM ET
Accession number0001193125-26-388631

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.